INTRODUCTION
The Notch pathway is involved in intercellular communication and it regulates homeostasis of several tissues by controlling self-renewal, apoptosis, differentiation and proliferation of cells (1) .
In mammals, Notch signals through four different receptors (Notch1-4) and five different ligands (Jagged 1-2, Delta-like (DLL)-1,-3 and -4). Binding of a ligand triggers a proteolytic cascade that ultimately leads to the release of the intracellular domain (ICD) of the Notch receptor. ICD migrates to the nucleus, and interacts with the transcriptional complex CSL (C protein-binding factor 1/Suppressor of Hairless/Lag 1) converting it from a transcriptional repressor to a transcriptional activator; this eventually translates into increased transcription of target genes, including members of the Hes and Hey families (2) . Increased Notch1 activity has been observed in various tumors (3) , including intestinal tumors, where it is partially accomplished by β-cateninmediated up-regulation of the Notch ligand Jagged-1 (4).
Aside from ligands, Notch activity is positively regulated by Musashi-1 (Msi-1), a RNA-binding protein of 39 kDa belonging to a conserved family of neural RNA-binding proteins composed of two RNA recognition motifs. Msi-1 binds the 3'-untranslated region of Numb, thus repressing its translation (5) . Numb is a membrane-associated negative regulator of Notch signaling, which induces endosome-mediated degradation of Notch ICD, thus preventing its transmigration to the nucleus and eventual signaling (6) . Numb involvement in asymmetric cell division is wellestablished: amounts of Numb and levels of Notch signaling are heterogeneous in daughter cells and this tunes cell differentiation versus stem cell maintenance (7).
Msi-1 was initially recognized as a RNA-binding protein required for asymmetric cell division of sensory organ precursor cells in Drosophila (8) . Msi-1 was also proposed to be required for asymmetric distribution of intrinsic determinants in the development of mammalian nervous system; indeed, its expression is enriched in undifferentiated neuronal precursors or neuronal stem cells (9) . Moreover, Msi-1 + cells were found in the mouse small intestine (10) and in the human Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 13, 2014; DOI: 10.1158/0008-5472.CAN- 5 colon at the base of the crypt compartment, where stem cells are considered to reside (11, 12) , thus indicating that Msi-1 could label colon stem cells. Remarkably, despite its relevance for key physiologic processes, the mechanisms of regulation of Msi-1 levels remain largely unknown.
We recently demonstrated that Notch3 levels are significantly up-regulated in primary and metastatic colorectal cancer (CRC) samples compared to normal mucosa (13) . Moreover, we also observed that a highly tumorigenic phenotype of CRC cells in xenograft models was associated with increased expression of various components of the Notch pathway. Forced expression of the active form of Notch3 mirrored the effects of DLL4 stimulation and promoted tumor formation (13) , supporting an oncogenic role for Notch3 in CRC cells. In addition, recent evidence from the literature demonstrated up-regulation of Msi-1 expression in both primary tumors and metastatic CRC samples, compared to normal colon tissue (14) .
Stimulated by the above observations, we sought to investigate whether Notch signaling could regulate Msi-1 levels in tumor cells. We found that Msi-1 expression is induced by DLL4 stimulation through a mechanism involving Notch3. In turn, increased Msi-1 levels sustain Notch1 signaling by repressing Numb. These observations highlight a novel feed-forward loop of regulation of Notch activity in cancer cells. 
MATERIALS AND METHODS

Cell lines, primary samples and in vitro culture
Human liver metastasis samples were obtained from 25 patients bearing colon or rectal cancer following informed consent. Immediately after resection, tissues were washed in cold phosphatebuffered saline (PBS) containing Penicillin/Streptomycin (500 U/ml), gentamicin (1 µl/ml) and amphotericin (1.25 µg/ml). Samples were processed as described elsewhere (12) . Briefly, the tissue was minced and incubated for 3 h at 37°C with collagenase (1.5 mg/ml) and hyaluronidase (20 µg/ml; both from Sigma-Aldrich, Milano, Italy) in DMEM/F12 medium (Gibco, Invitrogen, Carlsbad, CA). The digested material was centrifuged and sequentially filtered through 70 µm mesh; red blood cell lysis was performed at 37°C for 7 min in NH 4 Cl/KHCO 3 /EDTA buffer, and cell viability assessed by Trypan Blue dye exclusion. Before experimental use, cells were resuspended in DMEM/F12 medium, and maintained at 37°C in a 5% CO 2 humidified atmosphere in low-adhesion plates for 1 week.
LoVo is a colorectal cancer cell line derived from a metastatic nodule from the supraclavicular region (15), whereas MICOL-14 tum is a tumorigenic variant of MICOL-14, a cell line derived from a lymph node metastasis of rectal cancer (16 (18) were used at 10 μg/ml final concentration.
Flow Cytometry (FACS) Analysis
After 72 h of treatment, the cells were collected and incubated with Live/Dead dye (Invitrogen) for 30 min at 4°C, to stain dead cells. After washing in PBS, cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Non-specific binding was prevented by saturation with PBS/5% BSA, followed by incubation with rabbit anti-human Msi-1 qRT-PCR efficiency was in the range 95-105%.
Western blotting
After 72 h of treatment, the cells were harvested, lysed and subjected to SDS-polyacrylamide gel electrophoresis and Western blotting (WB). The membrane was saturated with PBS 5% non-fat dry milk (Sigma-Aldrich) for 1 h at room temperature. Immunoreactivity was evaluated by hybridization using the following antibodies: rabbit anti-Msi-1 (1:1,000 final dilution; Abcam), 
Transduction of cells with viral vectors
Lentiviral vectors encoding short harping RNA (shRNA) targeting human Notch3 (sh235, sh238) or a scrambled shRNA as a control were purchased from Sigma-Aldrich and used as previously reported (13) . The N3ΔE retroviral vector, encoding constitutively active forms of human Notch3 and the control MX vector have been described elsewhere (19) . The Notch2-ICD-encoding retroviral vector pMSVpuroICN2 was a kind gift of Adolfo Ferrando (Columbia University, NY).
The human DLL4-EGFP and the control retroviral construct lacking DLL4 have been previously described (20) . Vector stocks were generated by a transient three-plasmid vector packaging system, as previously described (21 
Statistical Analysis
Data of replicate experiments were shown as mean values ± Standard Deviation (SD).
Comparisons between groups were made by the Student's t-test. Figure 1A) . Importantly, these effects were blocked by anti-Notch2/3 but not by antiNotch1 mAb (Suppl. Figure 1A ). Since MICOL-14 tum cells express Notch1-3 but lack Notch4
receptors (13) stimulation. Moreover, in primary samples hDLL4 increased levels of all components of the Notch pathway tested (including Notch2, Notch3, Hes-1 and Hey-2), but not Notch1 (Suppl. Figure 1C ).
Next, we investigated the effects of DLL4 stimulation on the expression of stem cell-associated and differentiation markers. We observed that recombinant hDLL4 induced a 2-3-fold increase in
Msi-1 levels in MICOL-14 tum cells, which was largely blocked by anti-Notch2/3 treatment ( Figure   1A ). We also observed increased levels of Mucin-1 (Muc-1) and Mucin-2 (Muc-2) mRNA following Notch2/3 blockade in cultures analyzed ( Figure 1A ). Since Muc-1 is a marker of (25) , this finding supports previous observations indicating that Notch2/3 prevents colon progenitors from differentiating into secretory cells (26). In contrast, only marginal changes in Numb transcripts were detected in these experiments either in the presence or in the absence of hDLL4 ( Figure 1A ). To extend these findings, we stimulated LoVo cells with hDLL4.
In this case, however, only Msi-1 mRNA levels increased significantly, whereas no changes were detected in Muc-1, Muc-2 or Numb levels ( Figure 1B) . Moreover, treatment with anti-Notch 2/3 blocked the effects of hDLL4 on Msi-1 levels, and increased Muc-1 transcript levels ( Figure 1B) .
Finally, hDLL4 led to increased Msi-1 expression and to a corresponding decrease in Muc-1 levels also in primary cultures derived from liver CRC metastases, whereas only marginal changes were detected in Muc-2 and Numb levels, and these modulations were completely blocked by antiNotch2/3 ( Figure 1C ). Of note, treatment of primary tumor cultures with anti-Notch2/3 was associated with a significant reduction of Msi-1 expression and concomitant increase of Muc-1 and Muc-2 levels also in the absence of hDLL4 stimulation ( Figure 1C) , probably reflecting higher endogenous levels of Notch signaling, compared to MICOL-14 tum cells.
Up-regulation of Msi-1 levels was also observed following retroviral vector-mediated delivery of hDLL4 cDNA in MICOL-14 tum cells ( Figure 1D ), thus confirming results obtained with recombinant hDLL4. To test whether the effect of hDLL4 was restricted to Msi-1 expression, we addressed mRNA levels of several stem cell-associated genes in MICOL-14 tum and LoVo cells after hDLL4 stimulation. As reported in Figure 1E , DLL4 stimulation significantly increased Msi-1 levels and a trend towards increased ALDH1A expression was detected, whereas Bmi-1, EpCAM and EphB2 mRNA levels did not substantially change. Since it is reported that Notch signaling up-regulates ALDH (27), we evaluated by flow cytometry ALDH activity in both MICOL-14 tum and LoVo cells. As reported in Figure 1F , hDLL4 stimulation was followed by a significant increase in ALDH activity in both tumor cell lines. 
Effect of
Msi-1 modulation is Notch-3 dependent
To clarify which Notch paralog mainly controls Msi-1 expression, we overexpressed either Notch3 (N3) or Notch2 (N2) ICD in MICOL-14 tum cells by using retroviral vectors. Forced N3ICD expression increased Msi-1 levels by 3-fold, together with up-modulation of Hey-2 levels ( Figure   3A ). In contrast, over-expression of N2ICD increased Hey-2 but caused minimal changes in Msi-1 mRNA levels ( Figure 3A) . These results were confirmed in LoVo cells, where forced N3ICD expression strongly increased Msi-1, Notch3 and Hey-2 levels ( Figure 3B ). Altogether, these results fit the hypothesis that hDLL4 could up-regulate Msi-1 by a Notch3-mediated mechanism.
As a complementary approach, Msi-1 expression was investigated in MICOL-14 tum cells transduced by lentiviral vectors encoding Notch3-specific shRNA (sh235 and sh238). In agreement with our previous findings (13), Notch3 silencing resulted in 40% to 60% decrease in Notch3 mRNA levels ( Figure 3C ), compared to control shRNA cells; in addition, significantly lower levels of Msi-1 and Hey-2 were recorded upon Notch3 silencing, compared to control cells ( Figure 3C ). In line with these in vitro findings, IHC analysis demonstrated very low Msi-1 expression in xenotransplanted tumors generated by MICOL-14 tum cells with attenuated Notch3 levels ( Figure 3D ). Moreover, treatment of MICOL-14 tum xenografts with anti-Notch2/3 mAb caused a small but significant reduction of tumor burden measured by optical imaging ( Figure 4A ), associated with marked reduction of Msi-1 expression, increased Muc-1 levels ( Figure 4B ) and reduction of cell proliferation, measured by Ki67 staining ( Figure 4C ).
To strengthen these findings, we decided to further investigate the in vivo consequences of Notch3 inhibition on Msi-1 levels in patient-derived tumor xenografts. First, we mined gene expression data from a large collection of patient-derived xenografts of metastatic colorectal carcinomas (22) and Msi-1 is a well-recognized colon stem cell marker (11, 12) and one of the canonical features of cancer stem cells is their ability to form spheroids when cultured under specific in vitro culture conditions. We thus wondered whether experimental reduction of Msi-1 expression could affect the number of spheroid-forming cells. To test this hypothesis, we performed an ELDA assay with primary tumor cultures in the presence or in the absence of anti-Notch2/3 mAb. As shown in Figure 5A , the frequency of spheroid-forming cells was significantly reduced in the presence of the anti-Notch2/3 antibody from 1/738 to 1/239. Similar results were obtained for LoVo and MICOL- 
Effect of Notch3 modulation on Notch1 protein
Since Numb is an established negative regulator of Notch1 ICD downstream of Msi-1 [21] and Notch3 regulates Msi-1 expression, we argued that Notch3 could indirectly behave as a regulator of activated Notch1 levels. Indeed, stimulation with hDLL4 was followed by increased nuclear levels of activated Notch1 in MICOL-14 tum cells ( Figure 6A ), which are known to respond to hDLL4 stimulation mainly through Notch3 receptors (see Suppl. 
DISCUSSION
Although tumor cells often express multiple Notch paralogs, the reciprocal interplay between these receptors is not well understood. In T acute lymphoblastic leukemia (T-ALL), where activating mutations of Notch1 are common, Notch3 is considered as a canonical transcriptional target of Notch1 (28) . Notably, Notch3 can also contribute to the oncogenic process in T-ALL, as shown by genetic studies in transgenic mice (29) , although its transcriptional activity may be weaker compared to Notch1 due to the lack of the transactivation domain (30) . In solid tumors, Notch3 signaling accounts for oncogenic features in breast (31), ovarian (32), lung (33) and colorectal cancer (13) . However, as tumor samples often simultaneously co-express Notch1 receptors, it is difficult to address the real contribution of Notch3 to Notch signaling in tumor cells. In particular, whether Notch3 -in addition to its transcriptional activity on target genes shared with Notch1 -could influence Notch1 signaling by other routes has not been as yet investigated. expression and a corresponding increase in Muc-1 levels also in the absence of DLL4 stimulation. This finding might reflect higher endogenous Notch activity in primary tumor cells compared to colon cancer cell lines, as previously observed by others (36) . Although the experiments with antiNotch2/3 mAb do not allow dissecting the contribution of these two receptors in the regulation of Msi-1 levels, the key role played by Notch3 is strongly supported by shRNA-mediated silencing of These findings may be of relevance for physiological processes as well as for tumor development.
In this respect, it is interesting to note that DLL4 stimulation was associated with markedly increased ALDH1A expression and ALDH activity. ALDH has been reported to be a specific marker for colon stem cells and it has been used to track stem cell populations during colon cancer development (42) . These results confirm recent studies indicating that Notch signaling regulates ALDH activity both in normal stem cells and in cancer cells (27, 43, 44) . With regard to therapeutic implications, whether anti-Notch3 therapy could be clinically effective by promoting differentiation of colorectal cancer cells possibly increasing their sensitivity to chemotherapy is an intriguing issue that deserves further investigation. 
